Zhu et al., Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of Randomized, Double-Blind,.., medRxiv, doi:10.1101/2020.06.22.20136531
Meta analysis of Beigel and Wang RCTs showing remdesivir significantly decreased mortality (8.18% vs. 12.70%, RR 0.64 [0.44-0.92], p = 0.175).Currently there are 48 remdesivir studies and meta analysis shows:
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Efficacy and Safety of Remdesivir for COVID-19 Treatment: An Analysis of
Randomized, Double-Blind, Placebo-Controlled Trials
Yun Zhu1, M.D., Zhaowei Teng1,2,3, Ph.D., Lirong Yang3, Ph.D., Shuanglan Xu3,
M.D., Jie Liu3, M.D., Yirong Teng1, M.D., Qinggang Hao2, M.D., Dake Zhao2, Ph.D.,
Xiaolan Li4, M.D., Sheng Lu2, M.D., Yong Zeng1, M.D.
1
The Sixth Affiliated Hospital of Kunming Medical University, Yuxi, China
2
The Affiliated Hospital of Kunming University of Science and Technology,
Kunming, China
3
Graduate School of Kunming Medical University, Kunming, China
4
The Second Affiliated Hospital of Kunming Medical University, Kunming, China
All authors contributed equally to this paper.
Correspondence to:
Yun Zhu
The Sixth Affiliated Hospital of Kunming Medical University
21 Nieer Road, Yuxi 653100, Yunnan, China
Tel.: (86) 13887731212
e-mail: zhuyun8377@163.com
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
1
medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Abstract
BACKGROUND
Remdesivir, an inhibitor of viral RNA-dependent RNA polymerases, has been
identified as a candidate for COVID-19 treatment. However, the therapeutic effect of
remdesivir is controversial.
METHODS
We searched PubMed, Embase, and the Cochrane Central Register of Controlled
Trials, from inception to June 11, 2020 for randomized controlled trials on the clinical
efficacy of remdesivir. The main outcomes were discharge rate, mortality, and
adverse events. This study is registered at INPLASY (INPLASY202060046).
RESULTS
Data of 1075 subjects showed that remdesivir significantly increased the discharge
rate of patients with COVID-19 compared with the placebo (50.4% vs. 45.29%;
relative risk [RR] 1.19 [95% confidence interval [CI], 1.05–1.34], I2 = 0.0%, P =
0.754). It also significantly decreased mortality (8.18% vs. 12.70%; RR 0.64 [95% CI,
0.44–0.92], I2 = 45.7%, P = 0.175) compared to the placebo. Data of 1296 subjects
showed that remdesivir significantly decreased the occurrence of serious adverse
events (RR 0.77 [95% CI, 0.63–0.94], I2 = 0.0%, P = 0.716).
CONCLUSION
Remdesivir is efficacious and safe for the treatment of COVID-19.
TRIAL REGISTRATION NUMBER
2
medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
This study is registered at the International Platform of Registered Systematic Review
and Meta-analysis Protocols (INPLASY202060046).
3
medRxiv preprint doi: https://doi.org/10.1101/2020.06.22.20136531; this version posted June 29, 2020...
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.